Category Press Releases

Sensei

Organigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the…

Read MoreOrganigram Announces Mailing of Management Information Circular in Connection with Annual General and Special Meeting

DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students

The DaVita Giving Foundation has awarded Western Governors University’s (WGU) Michael O. Leavitt School of Health (LSH) a $1 million grant over the next three years to support more than 1,500 nursing students in Start Early, a…

Read MoreDaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation

RevBio, Inc., announced that it has received approval from the U.S. Food and Drug Administration to start a 20-patient pilot clinical trial to examine the safety and efficacy of the…

Read MoreRevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation
Sensei

bluebird bio Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird bio” or “bluebird”) today announced the U.S. Food and Drug Administration (FDA) has approved LYFGENIA™ (pronounced as ‘lif-JEN-ee-uh’) (lovotibeglogene autotemcel), also known as lovo-cel, for…

Read Morebluebird bio Announces FDA Approval of LYFGENIA for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events

European Commission Approves Pfizer’s ELREXFIO for Relapsed and Refractory Multiple Myeloma

–Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory…

Read MoreEuropean Commission Approves Pfizer’s ELREXFIO for Relapsed and Refractory Multiple Myeloma